

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Inflazyme Pharmaceuticals Ltd.	11/16/2007
RECEIVING PARTY DATA	
Name:	Biolipox AB
Street Address:	Berzelius vag 3
Internal Address:	plan 5
City:	Solna
State/Country:	SWEDEN
Postal Code:	S-171 65
PROPERTY NUMBERS Total: 15	
Property Type	Number
Application Number:	60200617
Patent Number:	6635629
Patent Number:	7112580
Application Number:	11474066
Application Number:	11496052
Application Number:	10258950
PCT Number:	CA0100581
Application Number:	60293013
Patent Number:	6696580
Patent Number:	6982329
Application Number:	60463216
Application Number:	10825084
PCT Number:	CA0400566
Application Number:	10575689

500956746

PATENT
REEL: 023196 FRAME: 0533

CH \$600.00 60200617

PCT Number:

IB0403426

CORRESPONDENCE DATA

Fax Number: (206)682-6031

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 206-622-4900

Email: AmberM@SeedIP.com

Correspondent Name: Carol J. Roth

Address Line 1: 701 Fifth Avenue

Address Line 2: Suite 5400

Address Line 4: Seattle, WASHINGTON 98104

ATTORNEY DOCKET NUMBER:

310151.001

NAME OF SUBMITTER:

Carol J. Roth

Total Attachments: 21

source=310151_001_ASSIGN2#page1.tif
source=310151_001_ASSIGN2#page2.tif
source=310151_001_ASSIGN2#page3.tif
source=310151_001_ASSIGN2#page4.tif
source=310151_001_ASSIGN2#page5.tif
source=310151_001_ASSIGN2#page6.tif
source=310151_001_ASSIGN2#page7.tif
source=310151_001_ASSIGN2#page8.tif
source=310151_001_ASSIGN2#page9.tif
source=310151_001_ASSIGN2#page10.tif
source=310151_001_ASSIGN2#page11.tif
source=310151_001_ASSIGN2#page12.tif
source=310151_001_ASSIGN2#page13.tif
source=310151_001_ASSIGN2#page14.tif
source=310151_001_ASSIGN2#page15.tif
source=310151_001_ASSIGN2#page16.tif
source=310151_001_ASSIGN2#page17.tif
source=310151_001_ASSIGN2#page18.tif
source=310151_001_ASSIGN2#page19.tif
source=310151_001_ASSIGN2#page20.tif
source=310151_001_ASSIGN2#page21.tif



LSAID

ASSIGNMENT

WHEREAS, Inflazyme Pharmaceuticals Ltd. (hereinafter referred to as ASSIGNOR), a corporation of Canada having a place of business at 5600 Parkwood Way, Suite 425, Richmond, British Columbia, Canada V6V 2M2, is the sole and exclusive owner of the entire right, title and interest in and to all of the patent applications and patents listed in Exhibit A and is a joint owner with the University of British Columbia, having an address at Industry Liaison Office, 2194 Health Sciences Mall, IRC, Room 331, Vancouver, British Columbia, Canada V6T 1Z3, and the University of Alberta, having an address at Industry Liaison Office, 222 Campus Tower, 8625 - 112 Street, Alberta, Canada T6G 2E1, of the entire right, title and interest in and to all of the patent applications and patents listed in Exhibit B;

WHEREAS, Biolipox AB (hereinafter referred to as ASSIGNEE), a corporation of Sweden, having a place of business at Berzelius väg 3, plan 5, S-171 65, Solna, Sweden, is desirous of acquiring the entire right, title and interest in and to the aforementioned patents and patent applications;

NOW, THEREFORE, in consideration of the sum of One Canadian Dollar (\$1.00) paid to ASSIGNOR in hand, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR does hereby sell, assign and transfer unto said ASSIGNEE, its entire right, title and interest in and to the patent applications and patents listed in Exhibit A and its entire right, title and interest in and to the patent applications and patents listed in Exhibit B, and any and all patents issuing from any patent application listed in Exhibit A and Exhibit B, and any and all continuations, divisions, reissues, supplemental protection certificates, or extensions of any such patents and applications listed in Exhibit A and Exhibit B (collectively, the "Assigned Patents"), and the inventions and discoveries set forth therein, and ASSIGNOR's right to file applications on such inventions and discoveries, to be held and enjoyed by the ASSIGNEE, for its own use and behalf and the use and behalf of its successors and assigns, to the full end of the term or terms for which such patents may be granted as fully and entirely as the same would have been held and enjoyed by the ASSIGNOR had this sale and assignment not been made, and ASSIGNOR hereby authorizes and requests any official of any country whose duty it is to issue patents, to issue or transfer all Assigned Patents to ASSIGNEE, its successors



LSAID

and assigns, in accordance with the terms of the assignment, or otherwise as ASSIGNEE may direct.

This Assignment is binding on ASSIGNOR, its successors and assigns, and will inure to the benefit of the ASSIGNEE, its successors and assigns. Nothing in this instrument, express or implied, is intended or shall be construed to confer upon, or give to, any person, corporation or entity other than ASSIGNEE, its successors and assigns, any remedy or claim under or by reason of this instrument, or any terms, covenants or conditions hereof, and all the terms, covenants and conditions in this instrument shall be for the sole and exclusive benefit of ASSIGNEE and its successors and assigns.

This Assignment is effective as of November 16, 2007.

INFLAZYM PHARMACEUTICALS LTD. (ASSIGNOR)

By: [Signature]
Print Name Michael Higgett
Title: Chief Financial Officer
Date: Nov. 16, 2007

Province of British Columbia }
Country of Canada } ss.

I certify that I know or have satisfactory evidence that Michael Higgett is the person who appeared before me, and said person acknowledged that he signed this instrument and acknowledged it to be his free and voluntary act for the uses and purposes mentioned in the instrument.

Dated Nov. 16, 2007

Signature of Notary Public [Signature]

Printed Name CATHERINE E. WADE

HEENAN BLAIE LLP
#2200 - 1055 West Hastings Street
Vancouver, BC V6E 2E9
Direct: 604-691-1165 Fax: 1-866-698-6911

LSAID

BIOLIPOX (ASSIGNEE) -

By: T. Bjerke

Print Name Torbjörn Bjerke

Title: President & CEO

Date: 2007-11-15

)

) ss.

)

I certify that I know or have satisfactory evidence that _____ is the person who appeared before me, and said person acknowledged that he signed this instrument and acknowledged it to be his free and voluntary act for the uses and purposes mentioned in the instrument.

Dated _____

Signature of
Notary Public _____

Printed Name _____

This is to certify that
Mr Torbjörn Bjerke ---
has signed his name above.

Stockholm, November 26, 2007

Ex officio

Notary Public



LSAID

**EXHIBIT A
LSAIDS PATENTS AND PATENT APPLICATIONS I**

Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
REDACTED				
480117.407P1 Provisional United States	3-NITROGEN-6,7-DIOXYGEN STEROIDS AND USES RELATED THERETO	60/200,617	04/28/00	
480117.407 Non-provisional United States	3-NITROGEN-6, 7-DIOXYGEN STEROIDS AND USES RELATED THERETO	09/845,775 6,635,629	04/30/2001 10/21/2003 04/30/2021	60/200,617 filed 04/28/2000
480117.407C1 Non-provisional United States	3-NITROGEN-6,7-DIOXYGEN STEROIDS AND USES RELATED THERETO	10/624,946 7,112,580	07/21/2003 09/26/2006 08/20/2021	09/845,775 filed 04/30/2001 60/200,617 filed 04/28/2000
480117.407C2 Non-provisional United States	3-NITROGEN-6,7-DIOXYGEN STEROIDS AND USES RELATED THERETO	11/474,066	06/23/2006	10/624,946 filed 07/21/2003 09/845,775 filed 04/30/2001 60/200,617 filed 04/28/2000
480117.407C3 Non-provisional United States	3-NITROGEN-6,7-DIOXYGEN STEROIDS AND USES RELATED THERETO	11/496,052	07/28/2006	10/624,946 filed 07/21/2003 09/845,775 filed 04/30/2001 60/200,617 filed 04/28/2000
480117.407USPC National United States	3-NITROGEN-6,7-DIOXYGEN STEROIDS AND USES RELATED THERETO	10/258,950	04/30/2001	60/200,617 filed 04/28/2000 (National Phase of PCT/CA01/00345 filed 03/16/2001)
480117.407PC PCT	3-NITROGEN-6,7-DIOXYGEN STEROIDS AND USES RELATED THERETO	PCT/CA01/00581	04/30/2001	60/200,617 filed 04/28/2000

REDACTED

LSAID

Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
--	-------	-------------------------	---	--------------------------

REDACTED

LSAID

Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
--	-------	-------------------------	---	--------------------------

REDACTED

LSAID

Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
--	-------	-------------------------	---	--------------------------

REDACTED

LSAID

Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
--	-------	-------------------------	---	--------------------------

REDACTED

LSAID

Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
--	-------	-------------------------	---	--------------------------

REDACTED

LSAID

Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
--	-------	-------------------------	---	--------------------------

REDACTED

LSAID

Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
480117.409P3 Provisional United States	PROCESS DEVELOPMENT AND MANUFACTURE OF 5A- PROGEST-17 (20)-ENE-3A, 6A, 7B-TROIL & (Z)-3B, 6A, 7B-TRIHYDROXY-17 (20) PREGENE	60/293,013	05/22/2001	
480117.409 Non-provisional United States	PROCESS IMPROVEMENTS IN STEROID CHEMISTRY	10/154,432 6,696,580	05/22/2002 02/24/2004 05/22/2022	60/293,013 filed 05/22/2001
480117.409D1 Non-provisional United States	PROCESS IMPROVEMENTS IN STEROID CHEMISTRY	10/744,857 6,982,329	12/22/2003 01/03/2006	60/293,013 filed 05/22/2001

REDACTED

LSAID

Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
--	-------	-------------------------	---	--------------------------

REDACTED

LSAID

Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
--	-------	-------------------------	---	--------------------------

REDACTED

480117.412P1 Provisional United States	IDENE DERIVATIVES AS PHARMACEUTICAL AGENTS	60/463,216	04/15/2003	
480117.412 Non-provisional United States	IDENE DERIVATIVES AS PHARMACEUTICAL AGENTS	10/825,084	04/15/2004	60/463,216 filed 04/15/2003
480117.412PC PCT	IDENE DERIVATIVES AS PHARMACEUTICAL AGENTS	CA2004/000566	04/15/2004	60/463,216 filed 04/15/2003

REDACTED

LSAID

Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
--	-------	-------------------------	---	--------------------------

REDACTED

LSAID

Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
--	-------	-------------------------	---	--------------------------

REDACTED

480117.417USPC National United States	CRYSTALLINE FORMS OF 3-BETA-AMINO 17-METHYLENE ANDROSTANE-6-ALPHA 7-BETA-DIOL HYDROCHLORIDE	10/575,689	10/20/2004	60/512,679 filed 10/20/2003 FR 0312257 filed 10/20/2003 (National Phase of PCT/ IB2004/003426 filed 10/20/2004 [417PC])
480117.417PC PCT	FORMES CRISTALLINES DU CHLORHYDRATE DE 3-BETA-AMINO, 17-METHYLENE, ANDROSTANE-6-ALPHA, 7-BETA-DIOL	IB2004/003426	10/20/2004	60/512,679 filed 10/20/2003 FR 0312257 filed 10/20/2003

REDACTED

LSAID

Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
--	-------	-------------------------	---	--------------------------

REDACTED

LSAID

Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
--	-------	-------------------------	---	--------------------------

REDACTED

LSAID

EXHIBIT B
LSAIDS PATENTS AND PATENT APPLICATIONS II

Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
--	-------	-------------------------	---	--------------------------

REDACTED

LSAID

Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
--	-------	-------------------------	---	--------------------------

REDACTED

LSAID

Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
--	-------	-------------------------	---	--------------------------

REDACTED

LSAID

REDACTED

Page 21 of 21